BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by AlphaQuest LLC

AlphaQuest LLC raised its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 36.2% in the second quarter, Holdings Channel.com reports. The institutional investor owned 85,353 shares of the biotechnology company’s stock after buying an additional 22,707 shares during the period. AlphaQuest LLC’s holdings in BioCryst Pharmaceuticals were worth $765,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in BCRX. Assenagon Asset Management S.A. increased its holdings in shares of BioCryst Pharmaceuticals by 25,631.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock valued at $32,441,000 after purchasing an additional 3,606,566 shares during the period. Millennium Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the period. Nuveen LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $10,677,000. Jupiter Asset Management Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after purchasing an additional 971,040 shares during the period. Finally, Parkman Healthcare Partners LLC increased its holdings in shares of BioCryst Pharmaceuticals by 361.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,000,562 shares of the biotechnology company’s stock valued at $7,504,000 after purchasing an additional 783,681 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Stock Up 0.1%

Shares of BCRX stock opened at $7.20 on Monday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The business’s 50 day moving average is $7.70 and its two-hundred day moving average is $8.67. The company has a market cap of $1.51 billion, a PE ratio of -40.00 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same quarter last year, the business earned ($0.06) EPS. The company’s revenue for the quarter was up 49.5% on a year-over-year basis. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BCRX. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. Zacks Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. TD Cowen assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price objective on the stock. Wedbush increased their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $19.18.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.